DEVONIAN

CORPORATE PRESENTATION

December 2022

TSXv – GSD

OTCQB – DVHGF

Cautionary Statements

This corporate presentation ("Presentation") has been prepared by DEVONIAN HEALTH GROUP INC. ("DEVONIAN") with market information provided by various third-party sources which we believe are reliable and is being furnished solely for the purpose of considering a transaction involving DEVONIAN.

This Presentation contains descriptive materials, financial projections and other data compiled for the convenience of parties interested in contemplating a transaction involving DEVONIAN.

This Presentation is being delivered by DEVONIAN to you with the understanding that you will conduct your own independent investigation of those matters which you deem appropriate without reliance upon DEVONIAN or any materials set out in this Presentation.

Certain statements contained in this Presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws, including estimates, forecasts and projections regarding future performance. Such forward-looking statements, estimates, forecasts and projections:

i. reflect various assumptions concerning future industry performance, general business, economic and regulatory conditions, market conditions for DEVONIAN's products and other matters, which assumptions may or may not prove to be correct,

ii. are inherently subject to significant contingencies and uncertainties, many of which are outside the control of DEVONIAN,

iii. should not be regarded as a representation by DEVONIAN that such estimates, forecasts or projections will be achieved. Actual results can be expected to vary, and those variations may be material.

All summaries and discussions of documentation and/or financial information contained herein are qualified in their entirety by reference to the actual documents and/or financial statements. You will be entitled to rely solely on the representations and warranties made to you by DEVONIAN in a definitive written agreement relating to a transaction involving DEVONIAN, when and if executed, and subject to any limitations and restrictions as may be specified in such definitive agreement. No other representations and warranties will have any legal effect.

Forward-looking statements are frequently, but not always, identified by the use of words such as "expects," "is expected," "budget," "scheduled," "forecasts," "anticipates," "believes," "intends," "estimates," "potential," "possible," "projects," "plans," or variations (including negative variations) of such words and phrases, or similar expressions, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of DEVONIAN to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Although DEVONIAN has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Such statements, based as they are on the current expectations of management, inherently involve numerous import ant risks, uncertainties and assumptions, known and unknown, many of which are beyond the control of DEVONIAN. Certain statements in this Presentation are forward-looking statements, which may include, but are not limited to statements with respect to: the potential of Thykamine™ to successfully treat atopic dermatitis ("AD"), Radiodermatitis ("RD"), Hand and Foot Syndrome ("HFS") associated to chemotherapy and other autoimmune disorders and benefit such patients; DEVONIAN's expectations related to its preclinical studies and clinical trials, including the design and results of its Phase 2a clinical trial in mild-to-moderate ulcerative colitis patients of its enema formulation of Thykamine™, and of its Phase 2 clinical trial in mild-to-moderate atopic dermatitis in adult population of it cream formulation of number of factors.

Moreover, DEVONIAN's growth and future prospects are mainly dependent on the successful development, patient tolerability, regulatory approval, commercialization and market acceptance of its product candidate Thykamine™ and other products. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. Although DEVONIAN believes that expectations represented by forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance, if any, on any forward-looking statements included in this Presentation. The forward-looking statements contained in this Presentation are expressly qualified by this cautionary statement. The forward-looking statements contained herein are made as of the date of this Presentation, and DEVONIAN disclaims any obligation and disavows any intention to update publicly or revise such forward-looking statements, whether as a result of any new information, future event, results, circumstances or otherwise, except where required by applicable legislation or regulation.

In furnishing this Presentation, DEVONIAN does not undertake any obligation to provide you with access to any additional information. This Presentation shall not be deemed an indication of the state of affairs of DEVONIAN nor shall it constitute an indication that there has been no change in the business or affairs of DEVONIAN since the date hereof. This Presentation does not constitute an offer to accept any proposal but is merely a solicitation of interest with respect to a transaction involving DEVONIAN. DEVONIAN reserves the right to request the return of this Presentation at any time.

Please see DEVONIAN's public filings with the Canadian securities regulatory authorities, including, but not limited to, its management report for the years ended July 31, 2021, and 2020 and the quarter ended July 31, 2021, for further risk factors that might affect DEVONIAN and its business.

Corporate Snapshot

Devonian Health Group

Snapshot

A Leader in the Discovery, Research & Development (R&D) of **Botanical Drugs / Pharmaceuticals (prescriptions)** following **US-FDA**, **Germany-BfArM**, and Health Canada Regulations

Developing a Pipeline with a product – **Thykamine™** - targeting medical unmet needs in **Inflammatory Autoimmune Diseases**

State-of-the-Art **cGMP Extraction** Facility; **Worldwide Intellectual Property** complemented with Industrial Secrets; **Experienced Management** with an expertise in conducting clinical trials and bringing pharmaceuticals to market

Principal Asset **Thykamine™** ready to embark on **Phase 3 trial** for mid-to-moderate **Adult Atopic Dermatitis** and Phase 2 for **Pediatric Atopic Dermatitis.**

Secondary Asset **R-Spinasome®** - anti-oxidant - **generating revenues** as active ingredient of a cosmeceutical product line.

Altius Healthcare
Division of Devonian Health Group Inc.
Healthier Lives

Specialty pharmaceutical company with a primary focus of **in-licensing medicines** for **distribution in Canada**.

Strong Leadership And Advisory Boards

Management

Pierre Montanaro President & CEO	Dr André P. Boulet, PhD Chief Scientific Officer	Sybil Dahan, BSc. President, Altius Healthcare	Colette Laurin CPA, CA CFO	Dr Mostafa Akbarieh, PhD VP Regulatory Affairs	Dr Daniel Bouthillier, PhD VP Research
Burroughs Wellcome Marion Merrell Dow Hoechst Marion Roussel Aventis Pharmacia Pharmascience	Nordic Laboratories Marion Merrell Dow Hoechst Marion Roussel BioCapital L.P. Sipar L.P. (Bio)	Hoechst Abbott Laboratories, (Canada, US/Latin America, Nordic Europe) Triton Pharma Inc. Aspri Pharma Canada	Raymond Chabot Martin Paré (Now RCGT) National Bank of Canada	ICN Pharmaceuticals Ratiopharm Pangeo Pharma Genpharm Triton Pharma Aspri Pharma Canada	Merck Pharmaceutical

Advisory Boards

Pharmaceutical R&D Program

- Dr Louis Flamand, PhD, MBA (Laval University)
- Dr Suha Jabaji, Ph.D (McGill University)
- Prof François Malouin, PhD (Sherbrooke University)
- Dr John Trant, PhD (Windsor University)
- Dr George Zhanel, PhD (University of Manitoba)

Development of Pharmaceutical Products in Dermatology

- Dr Sam Hanna, MD, FAAD, DABD
- Dr Ian D.R. Landells, MD, FRCPC
- Dr Jaggi RAO, MD, FRCPC
- Dr Jerry Tan, MD, FRCPC Dermatology

State-of-the-Art Pharmaceutical grade (cGMP) Extraction Facility

PROCESSING FACILITY

- 1,625 square meters
- Located in Montmagny (Québec)
- Water system upgradable to produce injectables / sterile eye solutions



PHARMACEUTICAL GRADE

- Full scale facility with custom designed equipment
- **Full traceability ; QA/QP**
- **Pharmaceutical-grade** production facility meeting Cleanroom Standards

Unique Proprietary Technology

protected by Patents and Industrial secrets

SOURCING

BOTANICALS

Organic Baby Spinach

Pharma-grade Supply Chain to secure
full traceability « from seed to pill »

EXTRACTION

of ACTIVE BOTANICAL INGREDIENTS (ABI) with SUPREX™

SUPREX™ Process

Extraction and Processing methodology
protected through patents and industrial secrecy
Unique water-based process to
extract, purify, and stabilize
components from any species of plant or algae



DEVELOPMENT

of R_X BOTANICAL DRUGS (Botanical complexes)
And COSMECEUTICALS



Thykamine™

Unique Anti-Inflammatory delivering a
Pipeline within a Drug

Botanical Drug regulations

Less costly and condensed R&D program allowing for quick-to-market

NEXT WAVE IN PHARMACEUTICALS

- **Specific FDA regulations:** Botanical Drug Regulations
- The FDA has already approved a number of plant-based drugs
- More than 800 New Drug Research (IND) and Pre-IND (PIND) meeting requests in the past year (1,2)

BENEFITS OVER CHEMICALLY SYNTHESISED DRUGS

- **Faster preclinical development**, and as robust clinical program as for traditional drugs
- **Benefit of a botanical complex** over single chemical molecule
- Drug Identification Number (DIN) designation and Reimbursement status as traditional drugs
- **Less costly**
- **Up to 5 years market exclusivity** (US) with or without patent
- **Difficult to copy** / generic

1) Wu C., Lee S-L, Taylor C., et al. Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective, J. Nat. Prod., 83, 2, 552–562, January 24, 2020
2) Investigational New Drug (IND)

Devonian's Target Therapeutic Areas and Indications

in high value markets

THERAPEUTIC INDICATIONS	GLOBAL MARKET (Forecasted by 2026)
Atopic Dermatitis (Eczema) 15-30% of children Leadership Position Opportunity	US $21Bn[1]
Ulcerative Colitis (Inflammatory Bowel Disease) 0.2% of population	US $10 Bn[4]
Radiodermatitis / Hand and Foot Syndrome No effective topical therapies Leadership Position Opportunity	95% of patients treated by Radiotherapy[2] 60% of patients treated for Breast & Colon Cancer[3] Combined Estimated market : > $2.5 Bn

1. Atopic Dermatitis Treatment Market (2020 -2025); Market Data Forecast; Feb 2020
2. Presta G., Puliatti A., Bometti L. et al. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review. Int Wound J. 16:1433–1439, 2019
3. Nikolaou V, Syrigos K and Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opinion on Drug Safety, Vol. 15, No. 12, 1625–1633, 2016
4. Reports and Data, Feb 2020
5. The Insight Partners - 2019

R&D Program set for Phase 3 trial

In preparation for first entry into Market

DRUG DEVELOPMENT PIPELINE WITHIN A PRODUCT

DERMATOLOGY				
Indication	**Preclinical**	**Phase 1**	**Phase 2**	**Phase 3**
Atopic Dermatitis (Adult - Topical)				
Atopic Dermatitis (Pediatric - Topical)				
Hand and Foot Syndrome associated to Chemotherapy (Adult - Topical)				
Radiodermatitis Associated to Radiotherapy (Adult - Topical)				
INFLAMMATORY BOWEL DISEASE (GASTROENTEROLOGY)				
Ulcerative Colitis (Adult – Oral)				

Pipeline
In A Product

Thykamine™:
Inflammation under Control

- Ulcerative Colitis Phase 2a Proof of Concept Study

Positive impact on Ulcerative Colitis symptoms (UC)

in Phase 2 (proof of concept) trial





Safety: No Serious Drug Related Adverse Events

(1) A 2-Week Exploratory Randomized, Double-Blind, Parallel- Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical Study of Pur 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis, Integrated Report prepared by Focus Clinical Drug development GMBH. Data in House: Devonian Health Group, Inc.

Outstanding Anti-Inflammatory effect at day 21 in UC patients





* P < 0.05

(1) A 2-Week Exploratory Randomized, Double-Blind, Parallel- Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical Study of Pur 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis, Integrated Report prepared by Focus Clinical Drug development GMBH. Devonian Health Group Inc.

Thykamine™

- Inflammation under Control
- Ulcerative Colitis

- **Phase 2a P.O.C. Clinical Study in patients with mild-to-moderate distal ulcerative colitis (2)**
  - Rectal enema : Placebo, **250**, 500 and 1500mg O/D for 14 days
  - **Safe and well tolerated**
  - **Approx.1 point placebo-corrected improvements in the stool frequency/rectal bleeding scores = shift of symptom severity from moderate to mild at Day 14**
  - **Marked effects on established biomarkers of active inflammation**
    - CRP, hsCRP, ESR, FC, FL, LTB4

1) A Randomized, Double-Blind, Parallel-Group Single-Ascending Dose, Placebo-Controlled Safety and Tolerability Study of PUR 0110 Rectal Enema in Normal Healthy Volunteers. Study No. PG08-PUR 0210-FIN001. Final Report: October 13, 2009.
2) A 2-Week Exploratory Randomized, Double-Blind, Parallel-Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis. Study number: PG09-PUR 0210-002, July, 2013

Pipeline
In A Product

Potential to study **Thykamine™**: Corporate Focus on Dermatological inflammatory disorders

- **Atopic Dermatitis**
  - Adult
  - Pediatric
- **Hand & Foot Syndrome** associated to Chemotherapy
- **Radiodermatitis** associated to Radiotherapy

Adult Atopic Dermatitis (AD) Phase 2 Trial[1]

Setting Stage for Phase 3



PRIMARY ENDPOINT

Proportion of patients with an **IGA score of 0** (clear) or 1 (almost clear) and **with at least a 2-grade improvement in IGA score from baseline**

SECONDARY ENDPOINTS

Change from Baseline to Day 29 in:

* **IGA** score
* Body Surface Area **(BSA)**
* Eczema Area and Severity Index **(EASI)** score
* Patient assessment of **Pruritus**
* Dermatology Life Quality Index (**DLQI**) score
* Patient-Oriented Eczema Measure (**POEM**)

POPULATION

* Adults with a diagnosis of AD for at least 6 months
* Mild to moderate
* **Body surface area (BSA) affected of between 5% and 25%**

162 participants recruited from 13 Canadian sites

1) A 4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of three concentrations (0,05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) cream applied twice daily in Mild-to-Moderate Atopic Dermatitis, Data in-house, Devonian Health Group Inc., Feb 2021

Adult Atopic Dermatitis (AD) Phase 2 Trial[1]

Setting Stage for Phase 3



1) A 4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of three concentrations (0,05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) cream applied twice daily in Mild-to-Moderate Atopic Dermatitis, Data in-house, Devonian Health Group Inc., Feb 2021

Adult Atopic Dermatitis (AD) Phase 2 Trial[1]

Setting Stage for Phase 3



1) A 4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of three concentrations (0,05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) cream applied twice daily in Mild-to-Moderate Atopic Dermatitis, Data in-house, Devonian Health Group Inc., Feb 2021

Adult Atopic Dermatitis (AD) Phase 2 Trial Setting Stage for Phase 3[1]

Mean change in key secondary endpoints by treatment group over time.



A: Change in % BSA affected

B: Change in Pruritus

C: Change in DLQI score

D: Change in POEM score

a: p ≤ .05 vs baseline

b: p ≤ .01 vs baseline

c: p ≤ .001vs baseline

d: p ≤ .05 vs vehicle

e: p ≤.01 vs vehicle

f: p ≤.001 vs vehicle

1) A 4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of three concentrations (0,05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) cream applied twice daily in Mild-to-Moderate Atopic Dermatitis, Data in-house, Devonian Health Group Inc., Feb 2021

Adult Atopic Dermatitis (AD) Phase 2 Trial[1]

Setting Stage for Phase 3

Incidence of AEs, n (%) that were probably, possibly, or definitely related to study medication (safety population).

Severity	Adverse event	Vehicle (n=40)	PUR 0110 0.05% (n=44)	PUR 0110 0.10% (n=39)	PUR 0110 0.25% (n=39)
Mild	Eye disorders	0	0	0	1 (2.6)
	General disorders and administration site conditions	2 (5.0)	0	0	0
Moderate	Skin and subcutaneous tissue disorders	2 (5.0)	2 (4.5)	1 (2.6)	0
	General disorders and administration site conditions	1 (2.5)	0	0	0
Severe	Musculoskeletal and connective tissue disorders	0	1 (2.3)	0	0
	Skin and subcutaneous tissue disorders	2 (5.0)	1 (2.3)	1 (2.6)	1 (2.6)

— **Generally well-tolerated**

Similar rate of adverse events reported for placebo and Thykamine™

1) A 4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of three concentrations (0,05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) cream applied twice daily in Mild-to-Moderate Atopic Dermatitis, Data in-house, Devonian Health Group Inc., Feb 2021

Adult Atopic Dermatitis (AD) Phase 2 Trial

Competitive Landscape

Competitive landscape vs new chemical entities

Efficacy rate similar to drugs derived from chemical synthesis

Drug	Mechanism of action	Clinical development phase	Patient population	% Patients reaching primary endpoint ($p<0.05$)
Thykamine[1]	Immunomodulator	II	Adults	30.8% *
Crisaborole [2]	Phosphodiesterase Inhibitor (PDE4)	Marketed	≥ 3 months	32.8% *
PAC-14028[3]	TRPV1 antagonist	II b	Adults	38.3% *
OPA-15406[4]	Phosphodiesterase Inhibitor (PDE4)	II	> 10 years	20.9% *
Pimecrolimus[5]	Calcineurin Inhibitor	Marketed	> 3 months	34.8% **

* Primary Endpoint: IGA of clear (0) or almost clear (1) AND 2 point reduction from baseline IGA (ISGA)

** Primary Endpoint: IGA of clear (0) or almost clear (1)

** Thykamine : 46.2%

1) A 4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of three concentrations (0,05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) cream applied twice daily in Mild-to-Moderate Atopic Dermatitis, Data in-house, Devonian Health Group Inc., Feb 2021
2) Product Monograph, EUCRISA Ointment, 2 %; Pfizer, 2018
3) Lee YWW, Won C-H., Jung k> et al. Efficacy and safety of PAC-14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. British Journal of Dermatology, 180, 1030-1038, 2019
4) Hanifin JM., Ellis CN, Frieden IJ, et al. OPA-15406, a novel topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (A): A phase-II randomized, double-blind, placebo-controlled study. J AM ACAD DERMATOL, Vol 75 (2), 297-305, 2016.
5) Product Monograph, Elidel Cream 1%, Valeant Canada, 2014

Thykamine™ – Best-In-Class Potential

Targeting unmet needs in autoimmune and inflammatory diseases



- **Compelling efficacy** from Phase 2 clinical study in Adult population with Mild-to-Moderate Atopic Dermatitis (AD)
- **Fast onset of action**
- **Efficacy on AD similar to biotech products** issued from chemical synthesis
- **Positive effect on pruritis (itching)** associated to Atopic Dermatitis
  - ✓ No need for second pharmaceutical product
- Well tolerated with **side effects similar to placebo**
- Expected approval for **long term use**
- Expected **high acceptance** within the **Pediatric patient** population

Thykamine™

All in place
to go from Farm to Pharm™

Radiotherapy Supportive Care

Radiodermatitis associated to Radiotherapy

An unmet Medical Need [1,2,3]

- **In North America, Europe and Australia :** 50% of patients diagnosed with cancer will receive radiation therapy during their illness
  - 90% of these patients will develop some degree of radiodermatitis (radiation-induced skin reaction)
- **Impacts :**
  - Pain/discomfort
  - Patient's quality of life and well-being
  - May cause interruption/termination of radiation therapy
- **Current Therapies**
  - No gold standard for prevention/management
  - Physiopathology requires multitargets therapeutic approach
- **Botanical Drug as a new Therapy**
  - Leadership opportunity
  - **Thykamine™: Ready for Phase 2 Proof of Concept (POC) clinical study**

1) M Singh, Alavi A, Wong R, Akita S. Radiodermatitis: A Review of Our Current Understanding. A. J Clin Dermatol, 2016 ; 17:277-292
2) Ryan JL. Ionizing Radiation : The Good, the Bad, and the Ugly. Journal of Investigative Dermatology, 2012 ; 132 : 985-993.
3) Adis Medical Writers, Drugs Ther Perspect., 2016; 32:521-525
Image from : Radiotherapy icons created by Freepik - Flaticon

Chemotherapy Supportive Care

Hand & Foot Syndrome Associated To Chemotherapy

An Unmet Medical Need [1,2,3,4,5,6]

- **Hand & Foot syndrome (HFS), also known as palmoplantar erythrodysesthesia or acral erythema, is a well-documented adverse effect of numerous chemotherapeutic agents.**
  - Inflammatory response at the Hand and Foot levels
  - Up to 60% of patients may be affected by HFS.
- **Impacts :**
  - Pain/discomfort
  - Patient's quality of life and well-being
  - May cause diminution of chemotherapeutic dose/termination of therapy
- **Current Therapies**
  - Supportive treatments such as topical wound care, elevation, and cold compresses may help to relieve the pain.
  - Physiopathology requires multitargets therapeutic approach
- **Botanical Drug as a new Therapy**
  - Leadership opportunity
  - **Thykamine™: Ready for Phase 2 Proof of Concept (POC) clinical study**

1) Kwakman JM, Elshot YS, Punt CJA, and Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncology Reviews; volume 14:442, 57-73, 2020.
2) Nikolaou V, Syrigos K and Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opinion on Drug Safety, Vol. 15, No. 12, 1625–1633, 2016
3) Nagore E, Insa A and Sanmartin O. Antineoplastic Therapy–Induced Palmar Plantar Erythrodysesthesia ('Hand-Foot') Syndrome : Incidence, Recognition and Management. Am J Clin Dermatol 2000 Jul-Aug; 1 (4): 225-234.
4) Son H-S, Lee WY, Lee W-S, Yun SH, and Chun H-K. Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy. Yonsei Med J 50(6): 796-802, 2009.
5) Miller KK, Gorcey L, and McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol,Vol 71, Number 4, 787-794, 2014.
6) Komatsu H., Yagasaki K., Hirata K., and Hamamoto Y. Unmet needs in cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study. Eur. J. Oncol. Nursing, 38, 65-69, 2019.

Corporate IP

Intellectual Property Portfolio

All intellectual property **100%** owned by Devonian

U.S. and international patent estate covering	Indications	Four (4) Trade marks
• Extraction / Isolation / stabilization process • Composition • Route of Administration (oral; iv; ip; etc.) • Use	• Inflammation • Cardiovascular • Gastrointestinal	• Devonian ™ • Fram to Pharm ™ • PurGenesis ™ • Thykamine™



KEY ANTICIPATED MILESTONES WITHIN NEXT 24 MONTHS

Phase 2 Pediatric Atopic Dermatitis Top-line results	✓
Phase 2 POC Hand & Foot Syndrome Top-line results	✓
Phase 2 POC Radiodermatitis Top-line results	✓
Phase 3 Adult Atopic Dermatitis clinical trial	✓

Stock And Financial Information[1]

CAPITAL STRUCTURE

Stock Exchanges	TSXv: GSD
	OTCQB: DVHGF
TOTAL OUTSTANDING SHARES	**131,266,473**
Warrants	42,798,164
Stock Options	9,050,000
FULLY DILUTED SHARE CAPITAL	**183,114,637**

LONG-TERM DEBTS ($ MIL)

Secured Loan	3.5
TOTAL	3.6

1) As of November 8, 2022

All the right ingredients for success!

Unique position North American botanical pharmaceutical drug development

ONE

Faster & economical preclinical development

TWO

Thykamine™ outstanding anti-inflammatory effect with proven results in 2 indications

THREE

Near-term value creation opportunities with large Pharma

FOUR

Management solid track record of execution

FIVE

Thank You

DEVONIAN

www.groupedevonian.com

TSXv: GSD
OTCQB: DVHGF